- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Mark Cziraky, PharmD, CLS: The Future of Biosimilars
Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.
Transcript:
What do you see as the future for the biosimilar space?
Well, I think a big part of it is we’re hopeful that these therapies become a big opportunity to reduce costs in the healthcare system while getting the intended benefits of these therapies.
You look at the generic marketplace and biopharmaceuticals in general, and while it’s taken some time, there are significant cost savings to be appreciated from using generic therapies. So, if you apply that to the biosimilar marketplace, and hopefully we’ll see again significant cost-reductions in the acquisition costs in the use of these therapies, and we’ll see benefits in that area too.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
